Lipocine shares surge 12.0% after hours on positive interim safety data from Phase 3 PPD trial.

Lipocine Inc. (NASDAQ: LPCN) surged 12% in after-hours trading following the release of positive interim safety data from its Phase 3 trial of LPCN 1154 for postpartum depression. The independent Data Safety Monitoring Board confirmed no drug-related serious adverse events, excessive sedation, or treatment discontinuations among 47 of 80 participants who completed dosing. The trial, conducted entirely in outpatient settings, will continue as planned with topline results expected in Q2 2026. The company emphasized the compound’s favorable safety profile, including no dose reductions or consciousness loss, and highlighted LPCN 1154’s potential as a first-line treatment for PPD. These developments reinforced investor confidence in the drug’s advancement toward a 505(b)(2) NDA filing, aligning with the stock’s sharp post-announcement rally.